GlassScriptPhysician profile
Freddie Pasco Dial
NPI 1093894941
$7,164.66
in general payments reported to CMS, 2019-2025
22 companies · $2,052 in 2025
The $2,052 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $358 · 2021: $1,054 · 2022: $1,185 · 2023: $1,319 · 2024: $1,077 · 2025: $2,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,447.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,366.84 | 2020-2025 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $794.18 | 2021-2023 | Tepezza |
| Novo Nordisk INC | $579.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $566.63 | 2023-2025 | Tepezza, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $551.95 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $504.82 | 2019-2025 | Lokelma, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $466.81 | 2022-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $394.66 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $385.29 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $346.49 | 2024-2025 | Korlym |
| Dexcom, INC. | $280.71 | 2022-2025 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $235.34 | 2024-2025 | Yorvipath |
| Lilly USA, LLC | $209.15 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Recordati_rare_diseases_inc. | $133.13 | 2024-2025 | Isturisa, Signifor Lar |
| Abbvie INC. | $127.94 | 2020-2024 | Synthroid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $49.66 | 2021-2023 | Senza |
| Merck Sharp & Dohme LLC | $42.89 | 2022 | |
| Neurocrine Biosciences, INC. | $35.09 | 2025 | |
| Chiesi USA, INC. | $29.30 | 2025 | Mycapssa |
| Kyowa Kirin, INC. | $26.77 | 2025 | |
| Amphastar Pharmaceuticals, INC. | $19.56 | 2023 | Baqsimi |
| Cequr Corporation | $18.19 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Freddie Dial listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.